Higher dose semaglutide leads to greater weight loss in adults with type 2 diabetes
In short: A clinical trial involving 1,210 adults with type 2 diabetes, overweight, or obesity found that a weekly 2.4 mg dose of semaglutide was more effective for weight management than a lower 1.0 mg dose or a placebo. Participants receiving the highest dose saw significantly greater reductions in bodyweight over 68 weeks compared to those receiving the placebo.
This phase 3 study investigated whether increasing the semaglutide dose could improve weight outcomes in patients already managing type 2 diabetes. While the 2.4 mg dose was more effective for weight loss, it was also associated with more frequent adverse events, particularly gastrointestinal issues.
The study was a randomized, double-blind, placebo-controlled trial, though the long-term effects beyond 68 weeks remain unknown.
Why it matters: Increasing the semaglutide dose improves weight loss efficacy but increases the frequency of side effects.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Davies et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England).
To cite this card, link to https://intellectplus.co.uk/app/health-research-higher-dose-semaglutide-leads-to-greater-weight-loss-in-adul.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health · Latest · A–Z · All topics
